An Emotionally Special Milestone

November 15, 2017

By Tal Zaks, M.D., Ph.D.
Chief Medical Officer, Moderna

Today marks an emotionally special milestone for me, as a medical oncologist, and for our entire team.  This morning, we announced that we have dosed our first patient in the Phase 1 study of our personalized cancer vaccine, mRNA-4157.  We have an opportunity to advance a medicine that is so novel, so breakthrough, it could truly transform the treatment of cancer.  And that could enable us to help many, many patients more effectively fight this disease – and, for some, even cure it.

Read more



Proud, Passionate and Mission-Driven for Patients

October 19, 2017

By Annie Drapeau
Chief Human Resources Officer, Moderna

This afternoon we announced that, for the third year in a row, we have been named one of the top 10 employers in Science magazine’s annual Top Employers survey. We are incredibly proud of this recognition, and are honored to be named on this list with so many other companies that we admire.

Read more



Shedding light on our prophylactic vaccines’ mechanism of action

September 26, 2017

By Giuseppe Ciaramella, Ph.D.
Chief Scientific Officer, Infectious Diseases, Moderna

When I describe leading infectious disease research efforts at Moderna, I often say it’s a bit like being a kid in a candy shop. We have this amazing, versatile tool in our hands. And we’re pushing the boundaries of this platform technology’s capabilities by exploring a range of options simultaneously – both across therapeutic areas and within therapeutic areas.

Read more


Continuing to Gain Momentum

September 13, 2017

Stéphane Bancel, Chief Executive Officer, Moderna

2017 is a key inflection point for Moderna on our journey to make mRNA medicines a reality for patients.

Our big news: major steps forward for our therapeutic modalities …

Read more



Pioneering A Big Idea with An Unborrowed Vision

June 28, 2017

Noubar Afeyan, Ph.D.
Co-founder and Chairman, Moderna Therapeutics
CEO, Flagship Pioneering

In April 2015, Luke Timmerman wrote an article that appeared in Forbes titled, ‘The Oprahs of Biotech: People Who Can Go by First Name Only.’

‘Stéphane’ was among the names in Luke’s article.

Read more



Building The Digital Biotech Company

June 22, 2017

Stéphane Bancel, Chief Executive Officer, Moderna

My first leadership roles in the biopharma industry were within a large pharma company. This was a phenomenal experience. I gained a strong understanding of how organizational infrastructures support established, global R&D, manufacturing and commercial enterprises to advance medicines to help patients. But I also saw how silos of information,  a blend of analog processes and digital ones, and a lack of integration among heterogeneous systems and geographic locations led to many lost opportunities.

Read more



Advancing Disruptive mRNA Vaccines:  Opportunity and Obligation

May 4, 2017

Michael Watson, MB ChB, MRCP, AFPM
President, Infectious Diseases, Moderna

Evan Rachlin, MD
Senior Director of Strategic Planning, Moderna

As physicians by training, we’re often asked by friends and family why we made the decision to jump from clinical care to the biopharmaceutical space. The potential to bring new medicines to patients – medicines that can impact and improve many, many lives – is tantalizing.

What attracted both of us to Moderna specifically was its potential to bring not just one or two new medicines to market – but to possibly launch an entire new class of medicines that could help people impacted by many types of diseases. Go big or go home.

Read more



A Milestone Week at Moderna

April 28, 2017

Stéphane Bancel
Chief Executive Officer, Moderna

Dear All,

Welcome to the Moderna Blog.

We’ve considered launching this blog for a while – and this week seemed like the perfect time.

Why launch a blog?  We wanted to have a channel to communicate directly and more personally to all those interested in Moderna.

We plan to share insights and our viewpoint on important topics related to our company, our science and pipeline, and our industry as a whole. The blog also will give various team members a platform to talk about what motivates, inspires and drives them in their work here.

Read more